Unlock stock picks and a broker-level newsfeed that powers Wall Street.
IOB - Delayed Quote SEK

Elekta AB (publ) (0O5H.IL)

Compare
48.17
-2.57
(-5.07%)
At close: April 4 at 5:06:34 PM GMT+1
Loading Chart for 0O5H.IL
  • Previous Close 50.74
  • Open 50.20
  • Bid 47.18 x --
  • Ask 49.16 x --
  • Day's Range 47.86 - 50.45
  • 52 Week Range 47.86 - 88.65
  • Volume 116,990
  • Avg. Volume 517,701
  • Market Cap (intraday) 17.89B
  • Beta (5Y Monthly) 1.07
  • PE Ratio (TTM) 16.44
  • EPS (TTM) 2.93
  • Earnings Date May 28, 2025
  • Forward Dividend & Yield 2.40 (3.13%)
  • Ex-Dividend Date Feb 26, 2024
  • 1y Target Est 74.20

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

elekta.com

4,700

Full Time Employees

April 30

Fiscal Year Ends

Recent News: 0O5H.IL

View More

Performance Overview: 0O5H.IL

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

0O5H.IL
18.83%
OMX Stockholm 30 Index (^OMX)
7.89%

1-Year Return

0O5H.IL
40.26%
OMX Stockholm 30 Index (^OMX)
9.30%

3-Year Return

0O5H.IL
30.77%
OMX Stockholm 30 Index (^OMX)
7.06%

5-Year Return

0O5H.IL
30.21%
OMX Stockholm 30 Index (^OMX)
62.84%

Compare To: 0O5H.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0O5H.IL

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    18.44B

  • Enterprise Value

    23.72B

  • Trailing P/E

    17.71

  • Forward P/E

    11.57

  • PEG Ratio (5yr expected)

    1.19

  • Price/Sales (ttm)

    1.03

  • Price/Book (mrq)

    1.71

  • Enterprise Value/Revenue

    1.33

  • Enterprise Value/EBITDA

    8.22

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.45%

  • Return on Assets (ttm)

    4.91%

  • Return on Equity (ttm)

    11.63%

  • Revenue (ttm)

    17.37B

  • Net Income Avi to Common (ttm)

    1.12B

  • Diluted EPS (ttm)

    2.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.37B

  • Total Debt/Equity (mrq)

    66.01%

  • Levered Free Cash Flow (ttm)

    657.12M

Research Analysis: 0O5H.IL

View More

Company Insights: 0O5H.IL

Research Reports: 0O5H.IL

View More

People Also Watch